A study done on an open-label, prospective randomized study to compare the therapeutic effects of silymarin and vitamin E in NAFLD at the end of the 12-week treatment period showed that there was a significant decrease in the serum AST and ALT levels in both treatment groups. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.